NCT03829527: Robin

Evaluation of the Treatment Approach ROBIN

Status unknown NA Last updated 4 February 2019

What this trial tests

NA trial testing Psychotherapy in Clinical High Risk for Psychosis in 30 participants. Status unknown.

Timeline

1 September 2017

Primary endpoint
30 September 2022

30 September 2022

Quick facts

Lead sponsor	University of Zurich
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	30
Start date	1 September 2017
Primary completion	30 September 2022
Estimated completion	30 September 2022
Sites	1 location across Switzerland

Drugs / interventions tested

• Psychotherapy

Conditions studied

• Clinical High Risk for Psychosis — all drugs for Clinical High Risk for Psychosis →

Sponsor

University of Zurich

Who can join

Adults 14 to 18, any sex, with Clinical High Risk for Psychosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevention of schizophrenia and other psychotic disorders has led researchers to focus on early identification of individuals at Clinical High Risk (CHR) for psychosis and to treat the at-risk symptoms in the pre-psychotic period. Although at-risk symptoms such as attenuated hallucinations or delusions are common in adolescents and associated with a marked reduction in global functioning, the evidence base of effective interventions for adolescents at CHR state and even first-episode psychosis is limited. To fill this gap, the clinicians from the early intervention center in Zurich have developed the treatment approach "Robin" (standardized manual and smartphone App) for adolescents with high risk for developing a psychotic disorder. The treatment approach is based on existing therapy strategies for adolescents with first episode of psychosis and the available recommendations for adults with at-risk symptoms. The evaluation aims firstly to compare the efficacy of "Robin" in 30 CHR adolescents aged 14-18 to an active control group (treatment as usual) from a previous study. Primary outcome measures will be at-risk symptomatology, comorbid diagnosis, functioning, self-efficacy and quality of life. For the prospective intervention condition (16 weekly individual sessions + a minimum 4 family sessions), help-seeking adolescents with CHR for psychosis, aged 14-18, will be recruited over three years. At-risk and comorbid symptoms, functioning, self-efficacy and quality of life are monitored at six time points (baseline, during the treatment period, immediately after intervention, and 6, 12, and 24 months later) and compared to the respective measures of the active control group.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. Evaluation of the Combined Treatment Approach "Robin" (Standardized Manual and Smartphone App) for Adolescents at Clinical High Risk for Psychosis.
   Traber-Walker N, Gerstenberg M, Metzler S, Joris MR, et al · · 2019 · cited 8× · PMID 31244692 · DOI 10.3389/fpsyt.2019.00384
2. O1.1. ETRo: EVALUATION OF THE TREATMENT APPROACH “ROBIN” (STANDARDIZED MANUAL AND SMARTPHONE APP) FOR ADOLESCENTS WITH CLINICAL HIGH RISK FOR DEVELOPING A PSYCHOTIC DISORDER
   Traber-Walker N, Gerstenberg M, Metzler S, Bühlmann C, et al · · 2020
3. SIRS 2020 Abstracts
   · 2020
4. O1.2. REDUCING THE DURATION OF UNTREATED PSYCHOSIS IN A U.S. CATCHMENT: THE MINDMAP CAMPAIGN
   Srihari V, Ferrara M, Kline E, Li F, et al · · 2020
5. O1.3. BACK TO THE FUTURE: PREDICTING POPULATION NEED FOR PSYCHOSIS CARE BASED ON THE EPIDEMIOLOGY OF PSYCHOTIC DISORDERS IN ENGLAND, AN APPLIED BAYESIAN METHODOLOGY
   McDonald K, Ding T, Dliwayo R, Osborn D, et al · · 2020